Stephanie Venn-Watson | Source | Co-Founder, CEO at Seraphina Therapeutics
Stephanie Venn-Watson
Stephanie is the Co-Founder and CEO of Seraphina Therapeutics, Inc. Co-creator and Founder, Fatty15. A Serial Entrepreneur, Veterinary Epidemiologist, and Public Health Scientist, Stephanie has successfully launched two biotechnology companies, a translational research program, and community education projects in the for-profit, government, and non-profit sectors. Prior to founding Seraphina and Epitracker, she held roles at the National Marine Mammal Foundation, Defense Advanced Research Projects Agency (DARPA), the Centers for Disease Control and Prevention, and the World Health Organization. Stephanie holds over 40 patents and have 60 peer-reviewed scientific publications.
-
While our study further supported previously published anti-cancer and antimicrobial properties of C15:0, the discovered cell-based antidepressant properties of C15:0 are entirely new.
30 July 2022
-
30 July 2022article
C15:0, an Emerging Essential Nutrient, Demonstrates Anti-Depression, Antimicrobial, and Anti-Cancer PropertiesFor over 40 years, nutritional recommendations have emphasized the importance of decreasing all saturated fats in our diets. A new study, however, found that a healthy saturated fat has unique benefits that may be relevant to stemming a diverse set of health conditions.
-
Seraphina Therapeutics (https://www.seraphinatherapeutics.com)
Co-Founder, CEO